Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

47.9%

23 terminated/withdrawn out of 48 trials

Success Rate

32.4%

-54.1% vs industry average

Late-Stage Pipeline

3 trials in Phase 3/4

Results Transparency

1 of 11 completed trials have results

Key Signals

2 recruiting1 with results20 withdrawn

Enrollment Performance

Analytics

Phase 1

23(48.9%)

Phase 2

20(42.6%)

Phase 3

3(6.4%)

N/A

1(2.1%)

47Total

Phase 1(23)

Phase 2(20)

Phase 3(3)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (48)

Showing 20 of 48 trials

NCT00804154Phase 1Recruiting

Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

Role: collaborator

NCT04992247Phase 2Withdrawn

Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise

Role: lead

NCT05361915Phase 2Suspended

Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer

Role: lead

NCT05067257Phase 2Suspended

Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer

Role: lead

NCT03999658Phase 2Withdrawn

A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Role: lead

NCT05692908Phase 1Withdrawn

An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis

Role: lead

NCT05361954Phase 1Not Yet Recruiting

Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors

Role: lead

NCT04559412Phase 1Unknown

Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid Arthritis

Role: lead

NCT05308225Phase 1Active Not Recruiting

Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Role: lead

NCT05372783Phase 2Withdrawn

Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents

Role: lead

NCT05584709Phase 1Unknown

Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors

Role: lead

NCT04900428Phase 2Terminated

Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)

Role: lead

NCT05364840Phase 1Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers

Role: lead

NCT05060276Phase 1Withdrawn

Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors

Role: lead

NCT05472649Enrolling By Invitation

Long-Term Follow-Up of Patients Who Received Gene-Modified Cell Therapy

Role: lead

NCT04440007Phase 2Completed

Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19

Role: lead

NCT04885972Phase 2Unknown

Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis

Role: lead

NCT03818165Phase 1Terminated

Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases

Role: lead

NCT05007418Phase 1Recruiting

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

Role: lead

NCT04316442Phase 1Unknown

Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis

Role: lead